1. Academic Validation
  2. Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain

Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain

  • J Cereb Blood Flow Metab. 2017 Nov;37(11):3635-3639. doi: 10.1177/0271678X16668890.
Junchao Tong 1 Romina Mizrahi 1 Sylvain Houle 1 Stephen J Kish 1 Isabelle Boileau 1 Jose Nobrega 1 Pablo M Rusjan 1 Alan A Wilson 1
Affiliations

Affiliation

  • 1 Research Imaging Centre, Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, ON, Canada.
Abstract

In a recent clinical trial, the drug BIA 10-2474, a putative fatty acid amide hydrolase(FAAH) inhibitor, was responsible for severe adverse events (SAEs), including one death. To date, there has been little reliable information divulged about the potency of BIA 10-2474 at FAAH in the central nervous system. We synthesised BIA 10-2474 and determined its ability to inhibit FAAH ex vivo in rat brain using a FAAH selective radiotracer. BIA 10-2474 proved to be a potent FAAH Inhibitor with IC50s of 50-70 µg/kg (i.p.) in various brain regions. This information may be useful for determining the cause of the SAEs.

Keywords

Animal models; brain imaging; clinical trials; positron emission tomography; receptor imaging.

Figures
Products